Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial

Soo Heon Kwak, Kyung Ah Han, Kyung Soo Kim, Jae Myung Yu, Eun Sook Kim, Jong Chul Won, Jun Goo Kang, Choon Hee Chung, Seungjoon Oh, Sung Hee Choi, Kyu Chang Won, Sin Gon Kim, Seung Ah Cho, Bo Young Cho, Kyong Soo Park

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science